Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir

Objective:As the treatment of hepatitis C virus (HCV) infection has evolved to directly acting antiviral agents, the impact of these directly acting antiviral-only regimens on improving adherence to HCV treatment in HIV/HCV coinfected populations has not been evaluated. The study compared adherence to ledipasvir/sofosbuvir (LDV/SOF) in HCV monoinfected and HIV/HCV coinfected individuals.Design:Adherence was measured from participants in two phase 2 open-label studies (NCT01805882 and NCT01878799).Methods:HCV treatment-naive, genotype 1 study individuals [HCV monoinfected participants (N=20) and HIV/HCV coinfected participants, antiretroviral untreated (N = 13) or on combination antiretroviral therapy (N=37)] were treated with LDV (90mg) and SOF (400mg) administered as one tablet once daily for 12 weeks. Adherence was measured using three tools: medication event monitoring system cap, pill count, and patient report.Results:Participants were predominately African American (83%) and male (73%), with a median age of 59 years. Participants had prompt HCV viral load decline and high adherence rates (970.5% by medication event monitoring system). Participant adherence decreased significantly from early (baseline week 4) as compared with late (weeks 8-12) in therapy in all three groups - HCV monoinfected (P=0.01), HIV/HCV antiretroviral untreated (P=0.02), and HIV/HCV antiretroviral treated participants (P=0.01).Conclusion:Adherence to LDV/SOF in this urban population was high and comparable between HCV monoinfected and HIV/HCV coinfected participants regardless of antiretroviral use. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.